Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults (ENLIGHTEN 2)
← catalyst calendarSponsored by Lyra Therapeutics (industry) · LYRA — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
182actual
Sites
57
Countries
Belgium, Bulgaria, Germany +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-05-13 | actual | When the study began enrolling |
| Primary completion | 2025-04-02 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-04-02 | actual | The whole study's end, after follow-up |
| First posted | 2022-03-25 | actual | When this record first appeared on the registry |
| Results posted | 2026-02-19 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-02-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Chronic Sinusitis
- Chronic Rhinosinusitis (Diagnosis)
Interventions
- Drug: LYR-210
- Drug: Sham procedure control
- Other: Background therapy
Primary outcome
what the primary-completion date above is the date OFChange From Baseline (CFBL) in the 7-day Average Composite Score of 3 Cardinal Symptoms (3CS) in Participants Without Nasal Polyps
measured Week 24
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2024-03-29 · 1.5 MB · Prot_002.pdf
Statistical Analysis Planposted 2025-02-06 · 748 KB · SAP_003.pdf
Permalink · LYRA's whole pipeline · Catalyst calendar · Every registered study · What changed